MedTrace Logo

The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys

NCT00031109 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-10-15

No results posted yet for this study

Summary

The purpose of this study is to see if an investigational vaccine can make antibodies (proteins found in blood) in humans that will influence the course of an AIDS-like disease in monkeys. Hopefully, the results of this study can be applied to humans.

AIDS, which is caused by infection with HIV, is associated with many deaths and occurrences of disease. Although recent advances have been made in anti-HIV therapy for AIDS, there is no cure for HIV infection or AIDS, and drug therapy is too expensive for most infected populations. Some organizations are trying to make safe and effective vaccines that may prevent HIV infection and AIDS worldwide. Certain vaccines can generate specific antibodies in humans, but they do not inhibit HIV infection in laboratory tests. It is possible, however, that these antibodies may make HIV disease less severe following infection. For this reason, monkeys will be used to evaluate the role of specific human antibodies.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

gp160 MN/LAI-2

BIOLOGICAL

Aluminum hydroxide

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Tom Evans

  • Sharon Frey

Study Design

Purpose
PREVENTION

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Completion
2005-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031109 on ClinicalTrials.gov